Nuvectis Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
NVCT$21.08+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)Financial Statements.
The following financial statements are filed as part of this report:
| | | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID#1309) | F-2 | |
| Financial Statements: | | |
| Balance Sheets as of December 31, 2023 and 2022 | | F-3 |
| Statements of Operations for the Years Ended December 31, 2023 and 2022 | | F-4 |
| Statements of Redeemable convertible preferred stock and Stockholders’ equity (deficit) for the Years Ended December 31, 2023 and 2022 | | F-5 |
| Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | | F-6 |
| Notes to Financial Statements | | F-7 - F-25 |
NUVECTIS PHARMA INC.
INDEX TO FINANCIAL STATEMENTS
U.S. DOLLARS
| | | |
|---|---|---|
| | Page | |
| | | |
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C.P.A.s and PCAOB ID: 1309) | | F-2 |
| FINANCIAL STATEMENTS: | | |
| Balance Sheets | | F-3 |
| Statements of Operations | | F-4 |
| Statements of Redeemable convertible preferred share and shareholders’ equity (deficit) | | F-5 |
| Statements of Cash Flows | | F-6 |
| Notes to the Financial Statements | | F-7 - F-25 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.